Mosaic ImmunoEngineering (CPMV) EBITDA Margin (2010 - 2011)
Mosaic ImmunoEngineering (CPMV) posted quarterly EBITDA Margin of 1641.83% for Q4 2011, up 75191.0% year-over-year from N/an in Q4 2010, and down 174.37% quarter-over-quarter from 598.4% in Q3 2011.
Mosaic ImmunoEngineering (CPMV) EBITDA Margin (2010 - 2011) Analysis & Trends
Mosaic ImmunoEngineering's EBITDA Margin history runs 2 years deep, the most recent figure standing at 1641.83% for Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Mosaic ImmunoEngineering | 527,536.97 | 527,536.97 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2011 | -1,641.83% |
| Aug 31, 2011 | -598.40% |
| Nov 30, 2010 | -2,393.73% |
| Aug 31, 2010 | -1,684.65% |